Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Metadata
Title
Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125
Authors
Silke Reinartz
Uwe Wagner
Patrick Giffels
Ursula Gruenn
Harald Schlebusch
Diethelm Wallwiener
Publication date
01-06-2000
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 4-5/2000
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620000126

Other articles of this Issue 4-5/2000

Cancer Immunology, Immunotherapy 4-5/2000 Go to the issue

ORIGINAL ARTICLE

Influence of interferon γ on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attack

ORIGINAL ARTICLE

Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors

ORIGINAL ARTICLE

Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth

ORIGINAL ARTICLE

Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses

ORIGINAL ARTICLE

Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies

REVIEW

The immunological effects of taxanes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits